The molecular mechanisms involve the regulation of key metabolic pathways and genes, such as NNAT and SGK1, highlighting ISL’s potential as a therapeutic agent for obesity and related metabolic disorders. This evidence concerns the gene SGK1 and obesity due to melanocortin 4 receptor deficiency.